Did you mean bitopertin of ro-4917838 of r1626 of ビトペルチン?
Displaying drugs 576 - 600 of 9573 in total
Capecitabine
Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.
Approved
Investigational
Matched Description: … Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast ... converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of …
Matched Products: … CORRETAL(R) 150 MG …
Matched Products: … CORRETAL(R) 150 MG …
Trofinetide
Trofinetide is a novel synthetic analog of glypromate, also known as glycine–proline–glutamate (GPE), a naturally occurring protein in the brain and the N-terminal tripeptide of insulin-like growth factor 1 (IGF-1). Trofinetide was approved by the FDA on March 10, 2023, for the treatment of Rett syndrome,[L45718,L45748] which is an X-linked...
Approved
Investigational
Matched Description: … Trofinetide is a novel synthetic analog of [glypromate], also known as glycine–proline–glutamate (GPE ... [A258438] Trofinetide is believed to work by reducing inflammation and apoptosis of neurons. ... [A258438] Trofinetide was approved by the FDA on March 10, 2023, for the treatment of Rett syndrome,[ …
Cyproheptadine
Cyproheptadine is a potent competitive antagonist of both serotonin and histamine receptors. It is used primarily to treat allergic symptoms, though it is perhaps more notable for its use in appetite stimulation and its off-label use in the treatment of serotonin syndrome.
Approved
Matched Description: … Cyproheptadine is a potent competitive antagonist of both serotonin and histamine receptors. ... perhaps more notable for its use in appetite stimulation[L32519] and its off-label use in the treatment of …
Butylscopolamine
Butylscopolamine is a peripherally acting antimuscarinic, anticholinergic agent. It is used to treat pain and discomfort caused by abdominal cramps, menstrual cramps, or other spasmodic activity in the digestive system. It is also effective at preventing bladder spasms. It is not a pain medication in the normal sense, since it...
Approved
Investigational
Vet approved
Matched Description: … It is on the WHO Model List of Essential Medicines, the most important medications needed in a basic …
Rumex salicifolius var. mexicanus pollen
Rumex salicifolius var. mexicanus pollen is the pollen of the Rumex salicifolius var. mexicanus plant. Rumex salicifolius var. mexicanus pollen is mainly used in allergenic testing.
Approved
Matched Description: … Rumex salicifolius var. mexicanus pollen is the pollen of the Rumex salicifolius var. mexicanus plant …
Chlorphenesin carbamate
Approved
Vet approved
Withdrawn
Zopiclone
Zopiclone is a novel hypnotic agent used in the treatment of insomnia. Its mechanism of action is based on modulating benzodiazepine receptors. In addition to zopiclone's benzodiazepine pharmacological properties it also has some barbiturate-like properties.
Approved
Matched Description: … Zopiclone is a novel hypnotic agent used in the treatment of insomnia. ... Its mechanism of action is based on modulating benzodiazepine receptors. …
Microcrystalline cellulose
A polysaccharide with glucose units linked as in CELLOBIOSE. It is the chief constituent of plant fibers, cotton being the purest natural form of the substance. As a raw material, it forms the basis for many derivatives used in chromatography, ion exchange materials, explosives manufacturing, and pharmaceutical preparations.
Approved
Experimental
Investigational
Matched Description: … It is the chief constituent of plant fibers, cotton being the purest natural form of the substance. …
Hydroxyprogesterone caproate
Hydroxyprogesterone caproate is a synthetic steroid hormone that is similar to medroxyprogesterone acetate and megestrol acetate. It is an ester derivative of 17α-hydroxyprogesterone formed from caproic acid (hexanoic acid). Hydroxyprogesterone caproate was previously marketed under the trade name Delalutin by Squibb, which was approved by the U.S. Food and Drug...
Approved
Investigational
Matched Description: … It is an ester derivative of 17α-hydroxyprogesterone formed from caproic acid (hexanoic acid). ... preterm delivery in women with a history of preterm delivery, sparking a pricing controversy. ... approved Makena from KV Pharmaceutical (previously named as Gestiva) on February 4, 2011 for prevention of …
Chloroquine
Chloroquine is an aminoquinolone derivative first developed in the 1940s for the treatment of malaria. It was the drug of choice to treat malaria until the development of newer antimalarials such as pyrimethamine, artemisinin, and mefloquine. Chloroquine and its derivative hydroxychloroquine have since been repurposed for the treatment of a...
Approved
Investigational
Vet approved
Matched Description: … [A191655] It was the drug of choice to treat malaria until the development of newer antimalarials such ... Chloroquine is an aminoquinolone derivative first developed in the 1940s for the treatment of malaria ... a number of other conditions including HIV, systemic lupus erythematosus, and rheumatoid arthritis. …
Tildrakizumab
Tildrakizumab is a high-affinity, humanized, IgG1 κ antibody targeting interleukin 23 p19 that shows promise in the evolution of treatment strategy in chronic plaque psoriasis .
The Food and Drug Administration (FDA) approved ILUMYA (tildrakizumab-asmn) for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy...
Approved
Investigational
Matched Description: … The approved recommended dosage of ILUMYA is a subcutaneous injection of 100 mg at Weeks 0, 4, and every ... A study was performed on the pharmacokinetics of this drug on various ethnicities. ... high-affinity, humanized, IgG1 κ antibody targeting interleukin 23 p19 that shows promise in the evolution of …
Ethotoin
Ethotoin is a hydantoin derivative and anticonvulsant. Ethotoin exerts an antiepileptic effect without causing general central nervous system depression. The mechanism of action is probably very similar to that of phenytoin. The latter drug appears to stabilize rather than to raise the normal seizure threshold, and to prevent the spread...
Approved
Matched Description: … The mechanism of action is probably very similar to that of phenytoin. ... seizure activity rather than to abolish the primary focus of seizure discharges. ... drug appears to stabilize rather than to raise the normal seizure threshold, and to prevent the spread of …
Osimertinib
Osimertinib is an oral, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) drug developed by AstraZeneca Pharmaceuticals.[A7926,L43453] Its use is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in cases where tumour EGFR expression is positive for the T790M mutation as detected by FDA-approved testing...
Approved
Matched Description: … due to the presence of specific activating EGFR mutations within the tumour cells. ... [A7926,L43453] Its use is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC ... Approximately 10% of patients with NSCLC have a rapid and clinically effective response to EGFR-TKIs …
Givosiran
Givosiran is a small interfering RNA (siRNA) directed towards 5-aminolevulinic acid synthase, a critical enzyme in the heme biosynthesis pathway. It is manufactured by Alnylam Pharmaceuticals and was first approved for use in the United States in November 2019 for the treatment of adults with acute hepatic porphyria, a genetic...
Approved
Investigational
Matched Description: … patisiran]), a new class of drugs promising an important and exciting step forward in the treatment of ... Pharmaceuticals and was first approved for use in the United States in November 2019 for the treatment of ... [L10202] Givosiran represents an important step forward in the treatment of acute hepatic porphyria as …
Doxorubicin
Doxorubicin is a cytotoxic anthracycline antibiotic isolated from cultures of Streptomyces peucetius var. caesius along side with daunorubicin, another cytotoxic agent, in 1970.[A1575,A257709,A257614] Although they both have aglyconic and sugar moieties, doxorubicin's side chain terminates with a primary alcohol group compared to the methyl group of daunorubicin. Although its detailed...
Approved
Investigational
Matched Description: … [A1573,A257614,L45231] However, one of the major side effects of doxorubicin is cardiotoxicity, which ... Doxorubicin is a cytotoxic anthracycline antibiotic isolated from cultures of Streptomyces peucetius ... exert its effect through DNA intercalation, which eventually leads to DNA damage and the generation of …
Matched Categories: … CHOP-R chemotherapy regimen …
Matched Categories: … CHOP-R chemotherapy regimen …
Icodextrin
Icodextrin is an iso-osmotic peritoneal dialysis solution containing glucose polymers. It is used primarily for ambulatory peritoneal dialysis (CAPD) of diabetic patients and automated peritoneal dialysis (APD) for patients with end-stage renal disease. It is injected as a solution into the peritoneal cavity. The drug is absorbed via convective transport...
Approved
Investigational
Matched Description: … It is used primarily for ambulatory peritoneal dialysis (CAPD) of diabetic patients and automated peritoneal …
Lifitegrast
Lifitegrast is a FDA approved drug for the treatment of keratoconjunctivitis sicca (dry eye syndrome). It is a tetrahydroisoquinoline derivative and lymphocyte function-associated antigen-1 ( LFA-1) antagonist that was discovered through the rational design process. The ophthalmic solution was approved in July, 2016 under the trade name Xiidra. It has...
Approved
Matched Description: … onset of action and well tolerated profile in both local and systemic setting [A18805]. ... Lifitegrast is a FDA approved drug for the treatment of keratoconjunctivitis sicca (dry eye syndrome) ... It has shown to protect the corneal surface and alleviate the symptoms of dry eye syndrome with fast …
Cabotegravir
Cabotegravir, or GSK1265744, is an HIV-1 integrase inhibitor that is prescribed with the non-nucleoside reverse transcriptase inhibitor, rilpivirine.[A227668,L31188,L31193] Early research into cabotegravir showed it had lower oral bioavailability than dolutegravir, which resulted in the development of long acting monthly intramuscular injection formulation for cabotegravir.[A227668,L31193]
Cabotegravir was granted FDA approval on...
Approved
Investigational
Matched Description: … showed it had lower oral bioavailability than [dolutegravir],[A227668] which resulted in the development of …
Satralizumab
Satralizumab is a recombinant humanized monoclonal antibody targeted against human interleukin-6 (IL-6) receptors, similar to tocilizumab, which is produced in Chinese hamster ovary cells and based on an IgG2 framework. Satralizumab is used in the treatment of neuromyelitis optica spectrum disorder (NMOSD), a rare autoimmune inflammatory disorder of the central...
Approved
Matched Description: … permeability of the blood-brain barrier, which allows for the passage of pro-inflammatory mediators ... This novel mechanism effectively increases the duration of action of satralizumab, as it allows for single ... autoimmune inflammatory disorder of the central nervous system (CNS) involving demyelinating lesions …
Fosdenopterin
Molybdenum cofactor deficiency (MoCD) is an exceptionally rare autosomal recessive disorder resulting in a deficiency of three molybdenum-dependent enzymes: sulfite oxidase (SOX), xanthine dehydrogenase, and aldehyde oxidase. Signs and symptoms begin shortly after birth and are caused by a build-up of toxic sulfites resulting from a lack of SOX activity.[A230088,L32163]...
Approved
Matched Description: … resulting from a lack of SOX activity. ... of this debilitating disorder. ... The most common subtype of MoCD, type A, involves mutations in _MOCS1_ wherein the first step of molybdenum …
Enmetazobactam
Enmetazobactam is a penicillanic acid sulfone extended-spectrum beta (β)-lactamase (ESBL) inhibitor. Because ESBL enzymes can hydrolyze important antibiotics such as penicillins, broad-spectrum cephalosporins and monobactams, ESBL-producing bacteria poses challenges in the treatment of serious infections. The combination product of enmetazobactam and cefepime was first approved by the FDA on February...
Approved
Matched Description: … on February 23, 2024, for the treatment of complicated urinary tract infections. ... [A263276]
The combination product of enmetazobactam and [cefepime] was first approved by the FDA ... broad-spectrum cephalosporins and monobactams, ESBL-producing bacteria poses challenges in the treatment of …
Mirabegron
Mirabegron is a sympathomimetic beta-3 adrenergic receptor agonist used to relax the smooth muscle of the bladder in the treatment of urinary frequency and incontinence. It is unique amongst overactive bladder treatment options in that, unlike other treatments such as solifenacin and darifenacin, it lacks significant antimuscarinic activity, which is...
Approved
Matched Description: … these medications and their broad range of adverse effects. ... the bladder in the treatment of urinary frequency and incontinence. ... Mirabegron is a sympathomimetic beta-3 adrenergic receptor agonist used to relax the smooth muscle of …
Exenatide
Exenatide is a glucagon-like peptide-1 (GLP-1) analog . It activates the GLP-1 receptor and increases insulin secretion, decreases glucagon secretion, and slows gastric emptying to improve glycemic control . Exenatide was given FDA approval on April 28, 2005 . It is available as immediate- and extended-release formulations.[L42685,L42690] Bydureon, the brand...
Approved
Investigational
Matched Description: … [L42685,L42690] Bydureon, the brand name product of extended-release exenatide in an injectable suspension …
Tezacaftor
Tezacaftor is a drug of the cystic fibrosis transmembrane conductance regulator (CFTR) potentiator class. It was developed by Vertex Pharmaceuticals and FDA approved in combination with ivacaftor to manage cystic fibrosis. This drug was approved by the FDA on February 12, 2018. Cystic Fibrosis is an autosomal recessive disorder caused...
Approved
Investigational
Matched Description: … CFTR is active in epithelial cells of organs such as of the lungs, pancreas, liver, digestive system, ... Tezacaftor is a drug of the cystic fibrosis transmembrane conductance regulator (CFTR) potentiator class ... Alterations in the CFTR gene result in altered production, misfolding, or function of the protein and …
Displaying drugs 576 - 600 of 9573 in total